• Ep 6- Dispelling Myths About Biosimilars

  • Dec 15 2021
  • Length: 10 mins
  • Podcast

Ep 6- Dispelling Myths About Biosimilars

Listen for free

View show details

  • Summary

  • Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the proliferation of myths and misinformation about biosimilars, which can be difficult to counteract.

    In this episode, Zoe and Conner talk to a few medical professionals about the most common biosimilar falsehoods, and what can be done to stop their spread.

    Among the highlights in this episode:

    1:58 – The FDA begins cracking down on misinformation

    2:47 – Myth #1: Patients confuse biosimilar drugs with generic drugs

    3:06 – Doctors’ initial concerns about quality control

    3:38 – Hesitancy about ‘transferability’

    4:54 – Myth #2: Biosimilars won’t save money

    5:50 – Myth #3: Biologics are natural monopolies

    Contact Our Hosts:

    Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. zrothblatt@ghlf.org

    Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. cmertens@ghlf.org

    We’d love to hear what you think. Send your comments to BreakingDownBiosimilars@GHLF.org

    See omnystudio.com/listener for privacy information.
    Show More Show Less
Show More Show Less

What listeners say about Ep 6- Dispelling Myths About Biosimilars

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.